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Abstract
In tumor cells, two factors are abnormally increased that contribute to metastatic bone disease: 
Runx2, a transcription factor that promotes expression of metastasis related and osteolytic genes; 
and IL-11, a secreted osteolytic cytokine. Here, we addressed a compelling question: Does Runx2 
regulate IL-11 gene expression? We find a positive correlation between Runx2, IL-11 and TGFβ1, 
a driver of the vicious cycle of metastatic bone disease, in prostate cancer (PC) cell lines 
representing early (LNCaP) and late (PC3) stage disease. Further, like Runx2 knockdown, IL-11 
knockdown significantly reduced expression of several osteolytic factors. Modulation of Runx2 
expression results in corresponding changes in IL-11 expression. The IL-11 gene has Runx2, AP-1 
sites and Smad binding elements located on the IL-11 promoter. Here, we demonstrated that 
Runx2-c-Jun as well as Runx2-Smad complexes upregulate IL-11 expression. Functional studies 
identified a significant loss of IL-11 expression in PC3 cells in the presence of the Runx2-HTY 
mutant protein, a mutation that disrupts Runx2-Smad signaling. In response to TGFβ1 and in the 
presence of Runx2, we observed a 30-fold induction of IL-11 expression, accompanied by 
increased c-Jun binding to the IL-11 promoter. Immunoprecipitation and in situ co-localization 
studies demonstrated that Runx2 and c-Jun form nuclear complexes in PC3 cells. Thus, TGFβ1 
signaling induces two independent transcriptional pathways - AP-1 and Runx2. These 
transcriptional activators converge on IL-11 as a result of Runx2-Smad and Runx2-c-Jun 
interactions to amplify IL-11 gene expression that, together with Runx2, supports the osteolytic 
pathology of cancer induced bone disease.
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Tumor invasion into bone is associated with secretion of growth factors, cytokines and other 
signaling molecules by cancer cells that promote the vicious cycle of tumor and metastatic 
bone disease. Prostate cancer metastatic bone disease results in predominantly painful bone 
forming osteoblastic bone lesions, but it is now clinically recognized that osteolysis is also a 
component of the metastatic disease in the bone microenvironment during progression of 
prostate tumor growth [Morrissey et al., 2013; Sottnik and Keller, 2013]. Recent studies in 
mouse models have also identified the osteolytic component of prostate cancer tumor 
growth in bone [Akech et al., 2010; Dutta et al., 2014; Eswaraka et al., 2014; Fradet et al., 
2013; Ortiz and Lin, 2012; Zhang et al., 2015]. TGFβ1 and PTHrP are considered the major 
factors driving this ‘vicious cycle’ of metastatic bone disease [Buijs et al., 2011; Massague, 
2012; Weilbaecher et al., 2011]. While cancer cells that secrete PTHrP promote osteoclast 
differentiation, TGFβ1 stimulates cancer cells to express other osteolytic factors, including 
multiple matrix metalloproteinases [Dutta et al., 2014]. In the TGFβ1 pathway, 
phosphorylated receptor-regulated R Smads (Smad2/3) form complexes with the co-Smad 
Smad4, then, enter the nucleus to bind with other transcription factors, such as Runx2 and 
AP1 factors to regulate gene expression [Ikushima and Miyazono, 2010; Padua and 
Massague, 2009; Zaidi et al., 2002]. Similar to breast cancer cells, two deregulated osteoytic 
factors, the Runx2 transcription factor and the osteolytic cytokine IL-11, are highly 
expressed in metastatic prostate cancer cells [Akech et al., 2010; Pratap et al., 2008; Zhang 
et al., 2015]. Both these pathologic activities result in woven bone formation and loss of 
normal bone during progression of tumor growth.
Several interleukins are also secreted from different tumor cells and among these is the 
highly osteolytic cytokine IL-11 [Sottnik and Keller, 2013]. IL-11 is a cytokine secreted 
from mesenchymal, epithelial and tumor cells and it was found to be a valuable biomarker 
for tumor aggressiveness and prognosis in several cancers [Casimiro et al., 2012; Furuya et 
al., 2005; Necula et al., 2012; Xiang et al., 2012; Zurita et al., 2004]. IL-11 a plays an 
important role in inflammation, motility and invasion in cancer and also increases 
transcription of bone sialoprotein, linked with cancer metastasis to bone [Begley et al., 2008; 
Lay et al., 2012; Matsumura et al., 2014; Shen et al., 2012]. As an osteolytic factor, IL-11 
stimulates the development and/or survival of osteoclast progenitor cells [Calon et al., 2012; 
McCoy et al., 2013]. IL-11 is one of four highly overexpressed genes in bone metastatic 
breast cancer cells [Kang et al., 2003] and it was strongly associated with resorptive activity 
in breast cancer cells; however, no mechanisms were established [Mendoza-Villanueva et 
al., 2011]. Potentially relevant to the osteoblastic lesions in PC tumors, IL-11 has been 
reported to have osteogenic properties in normal bone cells [Matsumoto et al., 2012]. 
Elevated levels of IL-11 and its receptor IL-11Rα have been observed in PC tumors 
[Campbell et al., 2001; Kamradt et al., 2007]. The cytokine is long known to be induced by 
TGFβ1 signaling, stimulating IL-11 gene transcription via induction of AP-1 factors [Kang 
et al., 2003; Matsumoto et al., 2012; Tang et al., 1998a]. However, transcriptional 
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mechanisms contributing to its high level of expression in bone metastatic breast and 
prostate cells is understudied.
Previous studies have established that Runx2 mediates TGF/BMP signaling to promote 
metastatic bone disease by PC cells and contributes to expression of genes that promote both 
osteomimmetic and osteolytic properties of PC cells [Akech et al., 2010; van der Deen et al., 
2010; Wan et al., 2012; Yang et al., 2001; Zhang et al., 2015]. In response to TGFβ1 Runx2 
recruits Smads to unique subnuclear domains forming Runx2-Smad complexes [Javed et al., 
2008; Zaidi et al., 2002; Zhang et al., 2000]. Runx2-Smad is critical in facilitating osteolytic 
disease resulting from orthotopic growth of human breast and prostate tumor cells in the 
mouse [Akech et al., 2010; Pratap et al., 2008; Zhang et al., 2015]. Studies have further 
demonstrated a striking reduction of bone resorption by Runx2 RNAi in vivo in the 
intratibial model of metastatic bone disease [Akech et al., 2010; Pratap et al., 2008]. The 
Runx2 transcription factor promotes tumor growth and metastatic bone disease through 
multiple mechanisms: direct transcriptional regulation of invasion-associated and bone 
homing genes (e.g., VEGF, MMPs, osteopontin, bone sialoprotein); increased transcription 
of TGFβ1-induced bone resorbing genes through Runx2-Smad signaling and Runx2-Gli 
complexes mediating IHH-PTHrP signaling [Pratap et al., 2008] promoting proliferation, 
motility, immortality of tumor cells and the disruption of normal acini [Leong et al., 2010; 
Pratap et al., 2009]. These findings showed that Runx2 is highly expressed in breast and 
prostate cancer cell lines that metastasize to bone and that it plays important roles in 
supporting the osteolytic disease associated with tumor growth in bone.
In this study, to further understand the observed impact of knockdown of Runx2 in reducing 
prostate cancer-induced osteolytic disease in vivo [Akech et al., 2010; Zhang et al., 2015], 
we examined Runx2 regulation of the IL-11 gene. These studies identify for the first time 
that two TGFβ1 signaling pathways, via Smad co-receptors and induced AP-1, converge on 
Runx2 through Runx2-Smad and Runx2-c-Jun complexes at SBE and AP-1 sites within the 
IL-11 proximal promoter. This cooperativity of two distinct Runx2 complexes greatly 
amplifies IL-11 gene expression in response to TGFβ1. Together, Runx2 and IL-11 are 
mediating TGFβ1-induced osteolytic disease in prostate cancer.
METHODS
CELL LINES AND CELL CULTURE
Three PC cell lines were used in these studies to model PC progression during tumor growth 
in bone. LNCaP cells that are lymph node, but not bone, metastatic were used as a control 
cell line; PC3-L cells that produce mixed osteolytic and osteblastic lesions and have low 
Runx2 levels; and PC3-H cells that have high Runx2 levels and that exhibit aggressive 
osteolytic disease in mouse models, followed by mixed osteolytic and osteblastic lesions. 
Microsatellite analyses carried out by the University of Vermont DNA Analysis Facility 
were used to identify the genotype as authentic LNCaP and/or PC3 cells [Zhang et al., 
2015].
LNCaP cells and PC3-L cells were cultured in RPMI 1640 with 10% FBS, 10 mM non-
essential amino acids, 2 mM L-glutamine and 1 mM sodium pyruvate. PC3-H cells were 
Zhang et al. Page 3
J Cell Biochem. Author manuscript; available in PMC 2016 September 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
cultured in T-medium with 5% fetal bovine serum (FBS) [Huang et al., 2005]. All media 
were supplemented with 100 U/ml penicillin and 100 μg/ml streptomycin. Cell culture 
media and supplements were obtained from Invitrogen, Carlsbad, CA, with the exception of 
FBS, which was obtained from Atlanta Biologicals, Norcross, GA.
TGFβ1 AND BMP2 TREATMENT
For experiments involving growth factor additions, sub-confluent cell layers were first 
cultured in 1% charcoal-stripped media (Life Technologies, Carlsbad, CA) for 24 h. Some 
cultures were treated with the TGFβ inhibitor SB431542 at 5 μM for 1 h pre-incubation prior 
to TGFβ1 treatment, where indicated. Treatment was for 24 h, with vehicle control (DMSO), 
porcine TGFβ1 (10 ng/ml), or BMP2 (100 ng/ml) (R&D Systems, Minneapolis, MN). Cells 
were then harvested for protein detection by Western blot and for mRNA levels by qPCR.
WESTERN BLOT ANALYSIS
Cells were lysed in RIPA buffer (50 mMTris-HCl (pH 7.5), 150 mM NaCl, 1 mM 
Na2EDTA, 0.1% SDS, 1% NP-40, 0.5% sodium deoxycholate) containing 25 mM MG132, 
EDTA-free cOmplete Protease Inhibitor Cocktail (Roche, Nutley, NJ) and 1mM PMSF. 
Proteins were resolved by SDS-PAGE and transferred to PVDF membranes (EMD 
Millipore, Billerica, MA). Membranes were incubated with mouse anti-Runx2 monoclonal 
(MBL International Corporation, Woburn, MA), rabbit anti-Smad2/3 (Cell Signaling 
Technology, Danvers, MA), or rabbit anti-phospho-Smad2, rabbit anti-phospho-Smad3, 
rabbit anti-c-Jun (Cell Signaling Technology, Danvers, MA), rabbit anti-cdk2 polyclonal 
antibody (Santa Cruz Biotechnology, Dallas, TX). Proteins were detected using Clarity™ 
Western ECL Substrate (Bio-Rad Laboratories, Hercules, CA).
REVERSE TRANSCRIPTION-QUANTITATIVE PCR (qPCR)
Total RNA was isolated from cells using Trizol reagent according to the manufacturer’s 
protocol (Invitrogen, Carlsbad, CA) and then further purified using a DNA-Free RNA kit 
(Zymo Research, Irvine, CA). cDNA was synthesized using Superscript First-Strand 
Synthesis System (Invitrogen, Carlsbad, CA). qPCR was performed using SYBR Green 
Master Mix (Bio-Rad, Hercules, CA) and gene-specific primers shown in Table S1 in an 
ABI Prism 7000 real-time PCR instrument (Life Technologies, Carlsbad, CA). Data were 
normalized using human glyceraldehyde 3-phosphate dehydrogenase (GAPDH).
IL-11 ELISA ASSAY
Supernatants collected from cell cultures were analyzed for secreted IL-11 expression using 
the Human IL-11 Quantikine kit (R&D Systems, Minneapolis, MN), according to 
manufacturer’s instructions. All samples were measured in duplicate and a biological 
replicate assay was carried out.
siRNA TRANSFECTION
Cells at approximately 60–70% confluency were transfected with 500 nM siRNA targeting 
Runx2 or with 500 nM non-silencing control siRNA (NS siRNA) using lipofectamine 2000 
(Life Technologies, Carlsbad, CA) according to manufacturer’s instructions. “Control” 
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transfections, in which cells were exposed to Lipofectamine 2000 only, were also included 
where indicated. mRNA and protein knockdown was assessed 48 h after transfection.
ADENOVIRUS INFECTION
For studies involving expression of Runx2 wild-type (WT) and mutant proteins, adenoviral 
vectors containing Runx2 WT-IRES-GFP, Runx2-HTY-IRES-GFP, and Runx2-ΔC-IRES-
GFP, and GFP-only (infection-efficiency control) constructs under the control of the CMV5 
promoter were delivered to low Runx2 expressing PC-L cells using previously described 
methods [Afzal et al., 2005]. Preparation and purification of virus were performed using the 
Adeno-X Maxi Purification Kit (Clonetech, Mountain View, CA), according to the 
manufacturer protocol. After infection, cells were washed twice with serum-free medium, 
incubated for 24 h, and prepared for downstream analysis or cultured for TGFβ1 treatment, 
as described above.
CHROMATIN IMMUMOPRECIPITATION (ChIP)
For ChIP experiments, approximately 1×107 PC3-H cells with high endogenous Runx2 
expression were either single-crosslinked in 1% formaldehyde for 10 min at room 
temperature (RT) or dual-crosslinked in 2 mM disuccinimidyl glutarate (DSG) for 30 min 
with agitation at RT, washed with PBS and then treated with 1% formaldehyde for 10 min at 
RT with rotation. Formaldehyde crosslinking was halted by addition of 2.5 M Glycine to a 
final concentration of 125 mM. Crosslinked cells were then washed with ice-cold PBS, 
harvested by scraping, pelleted, and resuspended in nuclei isolation buffer A (50 mM 
HEPES pH 7.5, 140 mM NaCl, 1 mM EDTA, 10% glycerol, 0.5% IGEPAL CA-630. 0.25% 
Triton-X100, Roche cOmplete protease inhibitor) for10 min at 4°C with constant rotation. 
Nuclei were then pelleted by centrifugation, washed in washing buffer B (10 mM Tris-HCL 
pH 8.0, 200 mM NaCl, 1 mM EDTA, 1 mM EGTA, Roche cOmplete protease inhibitor), 
collected by centrifugation and resuspended in lysis buffer C (10 mM Tris-HCL pH 8.0, 100 
mM NaCl, 1 mM EDTA, 1 mM EGTA, 0.1% sodium deoxycholate, 0.5% N-laurylsarcosine 
Roche cOmplete protease inhibitor). Samples were then sonicated for 7 min (formaldehyde 
crosslinking) or 15 min (dual-crosslinking) using a Covaris S220 focused-ultrasonicator 
(Covaris, Woburn, MA) to reduce chromatin to an average size of 0.3 kb. Chromatin was 
then incubated overnight with Runx2 antibody (M-70, Santa Cruz Biotechnology, Dallas, 
TX), rabbit c-Jun antibody (Cell Signaling Technology, Danvers, MA) or rabbit IgG (EMD 
Millipore, Billerica, MA) at 4°C followed by Protein A Dynabeads (Life Technologies, 
Carlsbad, CA). Immune complexes were washed three times with low salt buffer (20 mM 
Tris-HCl pH 8.0, 1 mM EDTA, 0.1% SDS, 1% Triton-X100, 150 mM NaCl) once with high 
salt buffer (20 mM Tris-HCl pH 8.0, 1 mM EDTA, 0.1% SDS, 1% Triton-X100, 500 mM 
NaCl) and once with TEN buffer (50 mM Tris-HCl pH 8.0, 1 mM EDTA, 50 mM NaCl) and 
eluted into elution buffer (50 mM Tris-HCl pH 8.0, 10 mM EDTA, 1% SDS) at 55°C for 30 
min with agitation. Chromatin was then treated with RNase A for 2 h followed by Proteinase 
K for 2 h at 55°C. DNA was then recovered by phenol/chloroform/isoamyl alcohol 
extraction followed by ethanol precipitation. Recovered DNA was then used as a template in 
qPCR reactions using primer pairs specific for each gene of interest (Table S2).
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CO-IMUNOPRECIPITATION
PC3-H cells (TGFβ1 treated or not treated) were scraped into ice-cold PBS and pelleted by 
centrifugation. Cells were then lysed with lysis buffer (150 mM NaCl, 50 mM Tris, pH 8.0, 
1% IGEPAL CA-630, EDTA-free cOmplete protease inhibitor cocktail (Roche, Nutley, NJ), 
25 mM MG132) on ice for 20 min and centrifuged to pellet insoluble cellular debris. Runx2 
M70 antibody (Santa Cruz Biotechnology, Dallas, TX) or rabbit IgG (EMD Millipore, 
Billerica, MA) was added to supernatant and incubated at 4°C overnight with agitation. Fifty 
μl protein A/G PLUS Agarose beads (Santa Cruz Biotechnology, Dallas, TX) were then 
added and incubated at 4°C for 3 h. Protein-antibody complexes were then collected by 
centrifugation, beads were washed four times with lysis buffer, resuspended in 2 x SDS 
sample buffer (Bio-Rad Laboratories, Hercules, CA), containing 5% β-mercaptoethanol and 
boiled for 5 min. immunoprecipated proteins were separated by SDS-PAGE and transferred 
to PVDF membranes for Western blot analysis.
IMMUNOFLUORESCENCE MICROSCOPY
Cells were grown on gelatin-coated coverslips and processed for immunofluorescence 
microscopy as described previously [Young et al., 2007]. Antibodies were diluted in 1% 
BSA in PBS. The following primary antibodies were used in immunofluorescence 
experiments: mouse monoclonal RUNX2 (MBL International Corporation, Woburn, MA), 
goat polyclonal Smad3 (Santa Cruz Biotechnology, Dallas, TX) and rabbit polyclonal c-Jun 
(described above). Secondary antibodies used were goat anti-mouse-IgG conjugated to 
Alexa Fluor 488, donkey anti-goat-IgG conjugated to Alexa Fluor 594, and goat anti-mouse-
IgG conjugated to Alexa Fluor 594, all from Life Technologies, Carlsbad, CA. ProLong 
gold antifade reagent with DAPI (Life Technologies, Carlsbad, CA) was added to the cells 
before they were visualized. The cells were examined by fluorescence microscopy and 
images were captured and processed using Zen pro2011 (Carl Zeiss Microscopy, 
Thornwood, NY). Immunofluorescence signals were quantified by using the ImageJ 
software package (National Institutes of Health, Bethesda, MD).
STATISTICAL ANALYSIS
Data were expressed as the mean ± standard error of the mean (SEM). Statistically 
significant differences were determined using the Student’s t-test with Welch’s correction. 
p<0.05 was considered statistically significant.
RESULTS
IL-11 EXPRESSION RELATED TO TGFβ1 AND RUNX2 SIGNALING
To begin to elucidate mechanisms involving both Runx2 and IL-11 in mediating prostate 
cancer metastatic disease, we initially characterized the relationship between Runx2 and 
expression of TGFβ1 and IL-11 among three prostate cancer cell lines, PC3-L, PC3-H, and 
LNCaP (Fig. 1). qPCR results showed high levels and a positive correlation between Runx2, 
IL-11 and TGFβ1 expression in PC3-H cells (known to have aggressive osteolytic properties 
in vivo). In contrast, PC3-L cells have significantly lower Runx2 and TGFβ1 levels and 
nearly undetectable IL-11 expression compared to PC-3H cells (Fig. 1A). Notably, LNCaP, 
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a non-bone metastatic cell, exhibited no detectable levels of all three genes. Expression of 
Runx2 is 7-fold, IL-11 ~25-fold, and TGFβ1 4-fold higher in PC3-H than in PC3-L cells. 
We also confirmed expression of known osteolytic genes in these cells, RANKL and MMP2 
(data not shown, as reported in [Dutta et al., 2014]), as well as PTHrP, CSF2, and CTGF 
(Supplementary Fig. S1). These genes also correlated with IL-11 and Runx2 expression in 
PC3-H cells.
TGFβ1 and BMPs are secreted during bone resorption and increase tumor cell secretion of 
osteolytic factors and osteoblastic factors that stimulate stromal cells to cause pathologic 
bone formation. The response of IL-11 and Runx2 to TGFβ1 and BMP2 was examined in 
PC3-L cells using molecular markers: PAI-1 for TGFβ1 activity and ID1, a target gene of 
BMP2 stimulation (Fig. 1B). TGFβ1 modestly increased Runx2 expression in PC3-L cells 
(1.5-fold). In striking contrast, IL-11 gene expression was induced significantly by TGFβ1 
(7-fold), although not as high as the PAI-1 marker gene of TGFβ activity (20-fold 
upregulated). BMP2 treatment had no significant effect on Runx2 or IL-11 compared to 
non-treated PC3-L cells with the exception of ID1, as expected (Fig. 1B). We find that 
TGFβ-induced expression of IL-11 and PAI-1 is almost completely inhibited by the TGFβ1 
inhibitor SB431542 (in the presence or absence of exogenous TGFβ1 treatment) (Fig. 1C). 
In contrast, the same inhibitor had no significant effect on Runx2 expression. In addition, 
Western blot results showed that TGFβ1-induced phosphorylation of its co-receptor Smad2, 
which was completely inhibited by SB431542 (Fig. 1D). Furthermore, an ELISA assay 
showed secretion of IL-11 in response to TGFβ1 was prevented by the inhibitor (Fig. 1E). 
Together these findings show a positive correlation between IL-11, Runx2 and TGFβ1 
expression, with robust induction of IL-11, but only a modest increase in Runx2 in response 
to TGFβ1.
EXPRESSION OF OSTEOLYTIC GENES PTHrP AND RANKL RESPOND TO CHANGES IN 
IL-11
To further investigate the role of IL-11 in the context of the ‘vicious cycle’ of osteolytic 
bone disease, we addressed whether changes in IL-11 affected the expression of PTHrP and 
RANKL. Consistent with the finding that IL-11 is induced by TGFβ1 in PC3-L cells (Fig. 
1B), both PTHrP and RANKL expression can also be induced by TGFβ1 in the same cells 
(Fig. 2A). To determine the relationship between IL-11 expression and these osteolytic 
factors, IL-11 was selectively inhibited by RNA interference in PC3-H cells, which express 
high endogenous IL-11 levels (Fig. 2B). Effective knockdown (60–80%) of IL-11 was 
confirmed by assaying secreted IL-11 (Fig. 2B, left panel) and IL-11 mRNA expression 
(Fig. 2B, right panel). As a result, the expression of the osteolytic factors PTHrP and 
RANKL were significantly decreased upon IL-11 depletion (p<0.05) (Fig. 2C). Thus, in 
support of the hypothesized functional relationship between Runx2 and IL-11, we find that 
the same osteolytic genes increased by Runx2 transcription, PTHrP and RANKL, are also 
responsive to IL-11 knockdown. These results suggest a functional cooperation between 
Runx2 and IL-11 mediated by TGFβ1 in advanced prostate cancer cell lines.
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IL-11 EXPRESSION IS RELATED TO RUNX2-SMAD SIGNALING IN PROSTATE CANCER 
PC3 CELLS
To address the functional relationship between Runx2 and IL-11 gene expression, we first 
determined if Runx2-regulated IL-11. Runx2 was exogenously expressed in PC3-L cells 
(having low endogenous Runx2 levels) by adenovirus infection (Fig. 3A). The results 
showed that Runx2 can activate IL-11 gene expression in PC3-L cells (Fig. 3B). We then 
selectively inhibited Runx2 expression by RNA interference in PC3-H cells (Fig. 3C). 
Accordingly, Runx2 protein expression was almost completely depleted, along with an 80% 
reduction in Runx2 mRNA levels. This knockdown of Runx2 reduced IL-11 gene 
expression by 40–50%, again supporting a potential role for Runx2 in regulating IL-11 (Fig. 
3D).
Our previous studies showed that Runx2 enhances the TGFβ1 response in cancer cells 
through formation of a Runx2-SMAD complex (reviewed in Introduction). To determine 
whether this mechanism is also involved in IL-11 gene regulation, we utilized constructs 
expressing either wild-type Runx2 or two mutations (Runx2-HTY and Runx2-ΔC) that 
abrogate Runx2-Smad signaling [Zhang et al., 2015]. The two Runx2 mutant proteins retain 
DNA binding domain, but are not fully functional [Zhang et al., 2015]. Importantly, TGFβ1 
treatment efficiently induced phosphorylation of Smad2 in cells expressing WT Runx2 and 
the mutant proteins (Fig. 3E). When the Runx2 mutant proteins were overexpressed in the 
PC3-L cells, IL-11 gene expression was reduced by 50% compared to Runx2 WT 
(Supplementary Fig. S2 and Fig. 3F). In these same cells, in the presence of exogenous 
expression of WT Runx2, IL-11 expression increased ~8-fold. However, exogenous 
expression of Runx2-HTY and −ΔC mutant proteins exhibited a 50% reduction in TGFβ1-
stimulated activation of the IL-11 gene when compared with controls (Fig. 3F). These data 
strongly implicate TGFβ-Runx2-Smad signaling in regulation of IL-11 gene expression in 
advanced prostate cancer cells, in addition to the known TGFβ-AP1 pathway that increases 
IL-11 expression in numerous cell types.
RUNX2 AND C-JUN FORM A COMPLEX FOR UPREGULATION OF IL-11 GENE 
EXPRESSION
The above findings prompted an examination of direct binding of Runx2 in the IL-11 gene 
promoter, but only a single Runx2 site resides in the proximal promoter in the vicinity of 
two previously characterized AP-1 sites (Fig. 4A). Multiple Smad binding elements and 
several additional AP-1 consensus sites are located within 5 kb of the IL-11 promoter 
region. Even after optimizing several experimental conditions (e.g., testing of two lots of 
M-70 Runx2 antibody from Santa Cruz Biotechnology, Dallas, TX, lot #s E2410 and 
F0112), we could not detect direct Runx2 binding to the IL-11 gene. Supplementary Fig. S3 
displays the absence of Runx2 binding at several promoter regions enriched in Smad sites. 
Therefore, we considered the possibility of a Runx2-c-Jun complex involved in regulating 
IL-11 gene expression. Several members of the AP-1 family of transcription factors are 
proven regulators of the IL-11 gene dependent on the cell type [Bamba et al., 2003; Tang et 
al., 1998b; Tohjima et al., 2003; Yang and Yang, 1994]. Previous studies showed that 
Runx2 can augment c-Jun activation of the AP-1 binding site in the collagenase-3 promoter 
[D’Alonzo et al., 2002; Hess et al., 2001] and also regulates PTH [Selvamurugan et al., 
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1998]. Chromatin immunoprecipitation (ChIP) was therefore pursued with a c-Jun antibody 
which confirmed c-Jun binding within the proximal, as well as in the distal IL-11 promoter 
regions (Fig. 4B).
We further interrogated whether Runx2 regulated the IL-11 gene through direct interaction 
with c-Jun under TGFβ1 stimulation. In response to TGFβ1, protein levels of Runx2 and c-
Jun remained unchanged; however, levels of phosphorylated Smad were noticeably 
increased demonstrating activation of TGFβ1 signaling (Fig. 5A). In PC3-H cells, with and 
without TGFβ1 treatment, we examined formation of a Runx2-c-Jun protein-protein 
complex. In Fig. 5B, results of a co-immunoprecipitation show an interaction between 
Runx2 and c-Jun in PC3-H cells that is amplified in the presence of TGFβ1. Validation that 
the Runx2-c-Jun complex contributes to IL-11 expression is shown by a decrease in IL-11 
protein levels upon Runx2 depletion in the presence of constitutively high c-Jun protein 
(Fig. 5C). Data derived from immunofluorescence (IF) microscopy studies revealed nuclear 
co-localization of Runx2 and c-Jun in PC3-H cells, which was diminished by Runx2 
knockdown (Fig. 5D). Quantifying the IF intensity corroborated these observations, with the 
presence of Runx2, as well as c-Jun, significantly decreasing after Runx2 depletion (Fig. 
5E). Together these data provide compelling evidence for formation of a nuclear Runx2-c-
Jun complex.
The summation of our findings supported by biochemical, molecular and in situ cellular 
approaches, is that a circuitry exists in prostate tumor cells whereby TGFβ1 signals to: 1) 
AP-1 activity for induced levels of IL-11 by Runx2-c-Jun; and 2) the formation of Runx2-
Smad complexes that induce osteolytic factors PTHrP, RANKL. These findings reveal the 
cooperativity of multiple transcriptional regulators of the IL-11 gene induced by TGFβ1 that 
contribute to metastatic bone disease.
DISCUSSION
IL-11 is a bone marrow stromal fibroblast-derived cytokine, highly induced by TGFβ1 
through AP1 sites in the IL-11 promoter [Bamba et al., 2003; Tang et al., 1998b]. This 
inflammatory cytokine has long been associated with breast, and prostate and other tumors 
[Campbell et al., 2001]. Because of its role in invasion and as a secreted factor in breast 
cancer cells that contribute to osteolytic bone disease, we examined IL-11 functional activity 
in prostate cancer cells with the goal of determining regulation of the IL-11 gene by Runx2 
as a mechanism for increased IL-11 expression in metastatic PC3 cells. In addition, it was 
also necessary to identify the contribution of IL-11 to osteolytic disease. In this study, we 
show by IL-11 expression profiles in PC cell lines and by specific knockdown that IL-11 
promotes expression of several osteolytic factors (e.g., Runx2, RANKL, CSF2, CTGF, 
PTHrP, VEGF) which are also genes directly regulated by Runx2-co-regulatory protein 
complexes. Importantly we have demonstrated that IL-11 induction in prostate cancer cells 
is mediated through two TGFβ1-induced pathways, Smad and AP-1, resulting in formation 
of Runx2-Smad and Runx2-c-Jun interactions that, together, amplify expression of IL-11. 
Therefore, we clearly demonstrate that increased IL-11 expression, together with Runx2, is 
contributing to augmented expression of osteolytic genes in prostate cancer cells.
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The Runx2 transcription factor is involved in mediating the ‘vicious cycle’ of metastatic 
bone disease [Pratap et al., 2011]. Our key findings have provided evidence for a TGFβ1-
Runx2-IL-11 regulatory pathway that affects expression of the osteolytic drivers PTHrP and 
RANKL [Weilbaecher et al., 2011]. Supporting evidence includes: 1) a positive correlation 
between IL-11, Runx2 and TGFβ1 in the aggressive PC3-H cell line; 2) the barely detectable 
IL-11, low TGFβ1 and Runx2 levels in metastatic PC3-L cells that produce mainly 
osteoblastic lesions; and 3) the near absence of these factors in LNCaP non-bone metastatic 
cells. Moreover, a synergistic effect of TGFβ1 on Runx2 and IL-11 in promoting osteolytic 
bone disease was evidenced by the following observations: TGFβ1 has a minimal effect in 
modifying Runx2 levels but a significant fold induction of IL-11. PC3-L cells exposed to 
exogenous Runx2 causes IL-11 to become induced 2.5-fold, but importantly, in the presence 
of both TGFβ1 and Runx2, these cells exhibit in a 30-fold induction of IL-11 compared to 
either TGFβ1 or Runx2 alone. Furthermore, knockdown of Runx2 WT protein in PC3-H 
cells or expression of Runx2 mutant proteins that disrupt Runx2-mediated TGFβ1 signaling 
in PC3-L cells, reduced IL-11 induction by TGFβ1. These in vitro-defined mechanisms are 
consistent with in vivo studies that demonstrated reduced osteolytic disease by expression of 
the Runx2-HTY mutant that is not responsive to TGFβ1 signaling [Zhang et al., 2015]. 
Thus, these data strongly implicate IL-11 as direct target gene of Runx2 and supports the 
notion of cooperative activities amongst TGFβ1 in prostate cancer cells.
Based on the finding that Runx2 expression increases and knockdown of Runx2 decreases 
IL-11 in PC3 cells, we performed studies to identify more precisely the mechanism by 
which Runx2 regulates IL-11. Upon examining Runx2 sites in the IL-11-gene, many were 
clustered in far distal regions of the gene, but only one consensus sequence occurred in the 
promoter. The IL-11 gene promoter (a region ≤ −5 kb upstream of the TSS) contains 
multiple AP-1 sites and Smad binding elements (SBEs). Given the well-established property 
of Runx2 as a scaffolding protein [Stein et al., 2004], we identified Runx2-Smad and 
Runx2-c-Jun complexes induced by TGFβ signaling that highly upregulated IL-11 gene 
expression. Although we demonstrated a functional relationship between Runx2 and IL-11, 
surprisingly, we did not detect direct binding of Runx2 in the IL-11 gene. This is in contrast 
to robust c-Jun binding in proximal and distal promoter regions. These results may be a 
consequence of weak Runx2 interaction at a single site or possibly epitope masking due to 
the formation of a Runx2 multimeric complex with co-regulatory factors. Large Runx2 
complexes can include histone modifying enzymes, co-activators and co-repressors, and 
other co-regulators associated with cancer, such as AP-1, c-myc, p53, mediators of src 
signaling, HOXa10, PBX, WWOX, TLE and ETS-1 [Ali et al., 2012; Aqeilan et al., 2007; 
Gordon et al., 2010; Pratap et al., 2011; Schroeder et al., 2005; Yang et al., 2001; Yang et 
al., 2010]. Thus, although a Runx2 ChIP could not detect Runx2 binding to IL-11, all other 
evidences [Bamba et al., 2003] strongly indicate Runx2 regulation via Runx2-Smad 
complexes at SBEs. For example, mutant Runx2 proteins that disrupt TGFβ1 signaling, 
significantly reduce IL-11 expression and secretion. We have also demonstrated a Runx2-c-
Jun nuclear complex in prostate cancer cells by co-IP and in situ IF, as well as c-Jun binding 
across the IL-11 promoter. Collectively, our findings of multiple levels of IL-11 gene 
regulation reveal an integrated network of TGFβ and Runx2 signaling, resulting in increased 
IL-11 gene expression that contributes to aggressive disease.
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Both breast and prostate cancer-induced metastatic bone disease is a complex process 
involving interactions of tumor cells with stromal cells, osteoblasts, osteoclasts that destroy 
bone, resulting in disease morbidity and mortality [Sottnik and Keller, 2013; Weilbaecher et 
al., 2011]. TGFβ Receptor I Kinase Inhibitors are in clinical trials and drugs that inhibit 
osteoclastic bone resorption are clinically effective in reducing skeletal complications of 
malignancy, although individual patient variables must be considered [Iranikhah et al., 2014; 
Mathew and Brufsky, 2014]. There is a compelling need to develop novel therapeutic 
strategies that can block tumor cell endogenous and secreted factors that deregulate the 
normal homeostasis of bone [Deng et al., 2014]. From our studies, Runx2 and IL-11, each 
with far reaching consequences on the skeleton, may represent potential therapeutic targets, 
if specifically directed to the bone-homing tumor cell to prevent aggressive bone disease.
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Fig 1. IL-11 expression is related to TGFβ1 and Runx2 signaling
(A) Robust expression of Runx2, IL-11 and TGFβ1 in highly osteolytic PC3-H cell line, 
with low to undetectable expression in PC3-L and LNCaP cells. Plots show relative gene 
expression of Runx2, IL-11 and TGFβ1 in PC3-L, PC3-H and non-metastatic LNCaP cell 
cultures determined by qPCR. (B) Response of low Runx2-expressing PC3-L cells (control) 
to TGFβ1 or BMP2 treatment. Sub-confluent PC3-L cells were cultured in 1% charcoal 
stripped FBS for 24 h before treatment with DMSO-control, TGFβ1, or BMP2, as indicated. 
Plots show relative gene expression of TGFβ1-regulated genes, Runx2, IL-11, PAI-1, and 
ID1. (C) Inhibition of TGFβ1 signaling in PC3-L cells. Sub-confluent PC3-L cells were 
cultured in 1% charcoal stripped FBS for 24 h before treatment with DMSO-control, 
TGFβ1, TGFβ1 inhibitor SB431542 (SB),m and SB431542 pre-treatment, followed by 
TGFβ1 (SB + TGFβ1). Plots show relative gene expression of Runx2, IL-11, and PA-I-1. 
Data were normalized to GAPDH and are mean ± SEM of n=3 experiments analyzed in 
duplicate. (D) Western blot analysis of phospho-Smad2, (p-Smad2), Smad2/3, and Cdk2 in 
PC3-L cells treated as indicated. (E) ELISA analysis of IL-11 levels in culture media from 
cells treated as indicated. Values are mean ± SEM of n=3 experiments analyzed in duplicate. 
Data in panels A–C and E were statistically analyzed using the T-test with Welch’s 
correction: not significant (ns), *p<0.05, **p<0.01, ***p<0.001.
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Fig. 2. IL-11 regulates expression of osteolytic genes PTHrP and RANKL in PC3 cells
(A) Effect of TGFβ1 treatment on osteolytic gene expression in PC3-L cells. Relative 
MRNA expression of PTHrP and RANKL was determined using qPCR in PC3-L cells 
treated with DMSO-control or TGFβ1. (B) Secretion of IL-11 protein measured by testing a 
sample of the culture medium using ELISA following IL-11 knockdown using siRNA (NS 
siRNA: non-silencing control siRNA). (C) Expression of IL-11, PTHrP and RANKL mRNA 
following IL-11 knockdown in PC3-H cells compared to controls. Data in panels A and C 
were normalized to GAPDH and were statistically analyzed using the Student’s t-test with 
Welch’s correction: not significant (ns), * p<0.05, ** p<0.01.
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Fig. 3. Modulation of Runx2 expression and activity alters IL-11 mRNA levels and response to 
TGFβ1
A) Ectopic expression of Runx2 in PC3-L cells. PC3-L cells were infected with adenoviral 
GFP (control) and wildtype Runx2 expression constructs. Western blot analysis is shown, 
with Cdk2 as a loading control. (B) Gene expression analysis of Runx2 and induced IL-11 in 
PC3-L cells with overexpressed Runx2 GFP control, relative to GAPDH. (C–D) Runx2 
knockdown in PC3-H cells. (C) Western blot analysis of Runx2 protein in nuclear extracts 
48 h after mock transfection (Con), and transfection with siRNA targeting (Runx2) or a non-
silencing (NS) control siRNA. Lamin A/C was used as loading control. (D) Corresponding 
qPCR analysis for Runx2 and IL-11 expression. (E–F) Effect of Runx2 mutations on TGFβ1 
signaling (E) and IL-11 expression (F) in PC3-L cells. (E) Western blot analysis of Runx2, 
p-Smad2 and total Smad2 following infection with adenovirus expressing GFP, Runx2 WT, 
Runx2–HTY and ΔC mutants in the presence (+) and absence (−) of TGFβ1 treatment. Cdk2 
was used as internal control. (F) Corresponding analysis of IL-11 gene expression using 
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qPCR. Data in panels B, D and F were normalized to GAPDH. Values are mean ±SEM of 
n=3 experiments analyzed in duplicate. Data were statistically analyzed using the Student’s 
t-test with Welch’s correction: *p<0.05, **p<0.01***p<0.001.
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Fig. 4. c-Jun binding in the IL-11 promoter region
(A) Illustration of the IL-11 gene promoter region (+/− 5 kb). There is one Runx2 binding 
site ~2.5 kb upstream of the TSS, two nearby AP-1 sites and a third AP-1 site approximately 
100 bp upstream of the TSS, as well as eight SMAD binding sites. (B) ChIP assay. 
Chromatin was immunoprecipitated with c-Jun or control IgG antibody and analyzed using 
qPCR analysis with primers for the AP-1 sites in the proximal (left) and distal (right) 
promoter regions.
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Fig. 5. Runx2- and TGFβ1-induced c-Jun form a complex in the nucleus
(A) Western blot showing expression of Runx2, p-Smad3, and c-Jun in PC3-H cells at the 
indicated times in the presence or absence of TGFβ1 treatment. Lamin A/C was used as 
internal control. (B) Runx2 co-immunoprecipitation in PC3-H cells after TGFβ1 treatment. 
PC3-H cells were treated with TGFβ1 or DMSO-control, then immunoprecipitated using 
Runx2 or IgG control. The Western blot shown was probed with Runx2 and c-Jun 
antibodies, as indicated. (C–E) Runx2 silencing in PC3-H cells. (C) Western blot analyses of 
Runx2, c-Jun, IL-11 protein in non-transfected (control) cells or 48 h after transfection with 
Runx2 siRNA or a non-silencing (NS) control siRNA. Cdk2 was used as loading control. 
(D) Representative confocal images 48 h after delivery of Runx2 or a non-silencing (NS) 
control siRNA (Scale Bar = 20 μm). (E) Quantification of the immunofluorescence signal in 
panel D calculated using the ImageJ software package. Data are mean ±s.d, calculated using 
the average intensity of fewer random fields of view (~10 cells/field) in three independent 
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experiments. Statistical analysis (T-test with Welch’s correction) was used to compare the 
values of cells transfected with NS siRNA or Runx2 siRNA: ***p<0.001.
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